As of November 9, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Liminatus Pharma, Inc. The largest reported stake is Valetudo Therapeutics LLC's, at 14.3%. 4 filings are on record since February 20, 2026 (Schedule 13D/A, July 14, 2026).
Sell to companies like Liminatus Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Samda Biolab Co., Ltd. · Sole voting: 3,426,548 · Shared voting: 0 · Sole dispositive: 3,426,548 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-22
- · Reporting person: Valetudo Therapeutics LLC · Sole voting: 9,617,954 · Shared voting: 0 · Sole dispositive: 5,244,351 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-07-14
- · Reporting person: Ewon Comfortech Co., Ltd. · Sole voting: 1,126,397 · Shared voting: 0 · Sole dispositive: 5,500,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-06
- · Holder: Mitchell P. Kopin · Percent: 4.99% · SCHEDULE 13G
Liminatus Pharma, Inc. has 4 Schedule 13D or 13G filings on record since 2026-02-20. 3 holders' latest filing reports 5% or more of common stock , par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Valetudo Therapeutics LLC | 14.3% | 9,617,954 | SCHEDULE 13D/A, 2026-07-14 | 2026-07-02 |
| Ewon Comfortech Co., Ltd. | 10.9% | 5,500,000 | SCHEDULE 13G/A, 2026-07-06 | 2026-06-24 |
| Samda Biolab Co., Ltd. | 5.1% | 3,426,548 | SCHEDULE 13G, 2026-07-22 | 2026-07-02 |
| 4.99% | 2,065,885 | SCHEDULE 13G, 2026-02-20 | 2026-02-17 |
Holding shares or following this stake? See who's behind Liminatus Pharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Liminatus Pharma, Inc. and the records around it.
Liminatus Pharma, Inc. elsewhere on the record
- Acquisition Jul 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Liminatus Pharma, Inc.
Get an email when Liminatus Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Liminatus Pharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Liminatus Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Liminatus Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Valetudo Therapeutics LLC | 9,617,954 | 0 | 5,244,351 | 0 | SCHEDULE 13D/A, 2026-07-14 |
| Chris Kim | 9,617,954 | 0 | 5,244,351 | 0 | SCHEDULE 13D/A, 2026-07-14 |
| Ewon Comfortech Co., Ltd. | 1,126,397 | 0 | 5,500,000 | 0 | SCHEDULE 13G/A, 2026-07-06 |
| Samda Biolab Co., Ltd. | 3,426,548 | 0 | 3,426,548 | 0 | SCHEDULE 13G, 2026-07-22 |
The latest filing identifies Liminatus Pharma, Inc. by CUSIP 53271X108 and gives its principal executive office as 2251 Stern Goodman Street, Suite E, Fullerton, CA 92833 (SCHEDULE 13G, 2026-07-22).
What the percentages are based on
5.1%* * Percentage is calculated based on 67,160,362 shares of Common Stock outstanding on July 2, 2026.Samda Biolab Co., Ltd., SCHEDULE 13G, 2026-07-22
Source of funds (Item 3)
On June 24, 2026, Valetudo Therapeutics LLC ("Valetudo") transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd and retains voting power over such shares pursuant to a voting agreement. On July 2, 2026, Valetudo received 3,448,926 shares of common stock and 48,975.10742 shares of the Issuer's newly designated Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") as consideration paid to former members of InnocsAI LLC ("InnocsAI") in connection with the Issuer's acquisition of InnocsAI.Valetudo Therapeutics LLC, SCHEDULE 13D/A, 2026-07-14
Purpose of Transaction (Item 4)
Valetudo Therapeutics LLC
The information set forth in Item 3 above is incorporated into this Item 4 by reference. The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. Chris Kim serves as Chief Executive Officer and a director of the Issuer, and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as described in this Statement, each of the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons acquired the shares reported herein for investment purposes. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the shares of common stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-20 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-07-06 | Ewon Comfortech Co., Ltd. | 10.9% | SCHEDULE 13G/A |
| 2026-07-14 | Valetudo Therapeutics LLC | 14.3% | SCHEDULE 13D/A |
| 2026-07-22 | Samda Biolab Co., Ltd. | 5.1% | SCHEDULE 13G |
Questions about who owns Liminatus Pharma, Inc.
Who owns Liminatus Pharma, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Liminatus Pharma, Inc.: Valetudo Therapeutics LLC (14.3%, Schedule 13D/A, filed 2026-07-14), Ewon Comfortech Co., Ltd. (10.9%, Schedule 13G/A, filed 2026-07-06) and Samda Biolab Co., Ltd. (5.1%, Schedule 13G, filed 2026-07-22).
Who are the largest shareholders of Liminatus Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Liminatus Pharma, Inc. on this page are Valetudo Therapeutics LLC (14.3%), Ewon Comfortech Co., Ltd. (10.9%) and Samda Biolab Co., Ltd. (5.1%).
When did Valetudo Therapeutics LLC buy into Liminatus Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Valetudo Therapeutics LLC on this page is the Schedule 13D/A, filed 2026-07-14, reporting 14.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Liminatus Pharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 2, 2026 | Acquired InnocsAI LLC | — | Acquisition | Source |
| June 18, 2026 | Form D, private offering | $1.86M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Liminatus Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.